AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05756387 — intervention group
Intervention type: DEVICE
Intervention: Non-invasive ventilation
Description: NIV as in standard care
Study NCT06017024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microprocessor-controlled knee (MPK) assessment
Description: The subject will wear the microprocessor-controlled knee prosthesis for 4 weeks, and then reply questionnaires and achieve functional tests
Study NCT06304818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCTB14
Description: SCTB14,IV
Study NCT05722002 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: NSAID
Description: Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~* Ibuprofen 600 milligram (mg) by mouth every six hours as needed for pain (10 doses)~* Celecoxib 400 mg by mouth once then 200 mg every twelve hours as needed for pain (10 doses)~* Naproxen 500 mg by mouth once then 250 mg by mouth every eight hours as needed for pain (10 doses)
Study NCT05722002 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Opioid
Description: Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~* Oxycodone 5 mg by mouth every four to six hours as needed for pain, 10 doses~* Morphine 7.5 mg by mouth every four to six hours as needed for pain, 10 doses~* Hydromorphone 2 mg by mouth every four to six hours as needed for pain, 10 doses
Study NCT05722002 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: Acetaminophen 1000 mg by mouth every 6 hours around the clock for the first three days after surgery then as needed thereafter (20 doses).
Study NCT06401356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelabresib
Description: Small molecule inhibitor of bromodomain and extraterminal (BET) protein
Study NCT06416800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral; Tablet
Study NCT06416800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral; Tablet
Study NCT06416800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral; Tablet
Study NCT06416800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral; Tablet
Study NCT06416800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Oral; Tablet
Study NCT04789538 — intervention group
Intervention type: OTHER
Intervention: monofocal lens
Description: not applicable as patients are already implanted with the monofocal intraocular lens
Study NCT05304338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Gargling with 10 mL 0.2% Chlorhexidine
Study NCT05304338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oil Pulling
Description: In oil pulling therapy, a tablespoon of edible oil is placed in the mouth and swirled between the teeth for 15 to 20 minutes
Study NCT05304338 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled Water
Description: Gargling with 10 mL distilled water
Study NCT04856722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mini-PNL
Description: PCNL using miniature nephroscope. The procedure will be performed under general or regional anaesthesia under fluoroscopy guidance.
Study NCT04856722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIRS
Description: RIRS using flexible ureteroscope. The procedure will be performed under general or regional anaesthesia under fluoroscopy guidance. Holmium Laser lithotripter will be used for stone fragmentation.
Study NCT04856722 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SWL
Description: SWL using Dornier SII lithotripter. the procedure will be performed under sedoanalgesia, and fluoroscopy will be used for stone localization; for a maximum of 3 SWL session.
Study NCT04490486 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSCs
Description: 100 x 106 (100 million) UCMSCs delivered via peripheral intravenous infusion.
Study NCT04490486 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, a solution of 1% human serum albumin in Plasmalyte A, delivered via peripheral intravenous infusion
Study NCT06639061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hippocampal stimulation using repetitive transcranial magnetic stimulation (rTMS)
Description: We will use fMRI resting state data to personalize a TMS inhibitory stimulation to a cortical location that is the most strongly connected to a deeper left hippocampal target.~5 once a week sessions of rTMS will be delivered at 1-Hz stimulation frequency for 15 minutes following trauma memory reactivation.
Study NCT06639061 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation using repetitive transcranial magnetic stimulation (rTMS)
Description: We will use fMRI resting state data to personalize a TMS sham stimulation to a cortical location with near zero connectivity to a deeper left hippocampal target. 5 once a week sessions of rTMS will be delivered at 1-Hz stimulation frequency for 15 minutes following trauma memory reactivation.
Study NCT05000008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Moderate aerobic and resistance exercise programe
Study NCT05950919 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TASKPEN
Description: The package of integrated HIV/NCD services:~1. Integrated non-communicable/HIV care (one stop shop for services)~2. WHO PEN protocols, algorithm, \& training materials adapted for Zambia~3. Access to cardio-metabolic condition screening \& laboratory monitoring~4. Non-communicable disease-focused electronic medical record module~5. Strengthened NCD medication supply chain
Study NCT06577064 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral erector spinae plane block
Description: 30 ml of 0.2% ropivacaine will be injected in the plane between the ESM and sacrum on each side
Study NCT06577064 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sacral erector spinae plane block
Description: 30 ml of 0.2% ropivacaine will be injected in the plane between the ESM and sacrum on each side
Study NCT05879250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05879250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05879250 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo routine radiation therapy
Study NCT05879250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAT3 Inhibitor WP1066
Description: Given PO
Study NCT05879250 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Procedure
Description: Undergo removal or biopsy of tumor
Study NCT05003310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Stimulation
Description: Stimulation will be turned ON and applied during each day of the period.
Study NCT05003310 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Active Stimulation
Description: Stimulation will be turned ON and applied during each day of the period.
Study NCT05003310 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Stimulation
Description: Sham stimulation will be provided during the period
Study NCT05003310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib (2 mg) is administered daily during the period.
Study NCT05003310 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Baricitinib
Description: Baricitinib (2 mg) is administered daily during the period.
Study NCT05003310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background Treatment
Description: Stable dose of standard background treatment (e.g., csDMARD therapy)
Study NCT05003310 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Background Treatment
Description: Stable dose of standard background treatment (e.g., csDMARD therapy)
Study NCT05003310 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Background Treatment
Description: Stable dose of standard background treatment (e.g., csDMARD therapy)
Study NCT05729100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral carbohydrate-electrolyte solution
Description: Oral solution containing 10% glucose and electrolyte (in every 300 ml of fluid (contains 30 gr dextrose, 150 mg Natrium chloride, 366 mg Kalium chloride)
Study NCT05729100 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Standard clear fluid (water)
Study NCT06573606 — intervention group
Intervention type: DEVICE
Intervention: CX-HA and CS
Description: Sterile Isotonic ophthalmic solution
Study NCT04870385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5-week prevention program
Description: Online modular psychological prevention program featuring integrated elements of Islamic spirituality and Acceptance and Commitment Therapy (ACT).
Study NCT04870385 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Control group waitlisted to receive prevention program after completion of final data collection.
Study NCT06383910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Square Stepping Exercise
Description: The exercise is performed on a thin exercise mat divided into 40 small squares. Participants are shown specific step patterns on this mat and are instructed to repeat the same step pattern until the end of the exercise mat. Once a pattern is completed on the exercise mat, its mirror-image pattern is also performed. The basic pattern is repeated 3-5 times, followed by the same number of repetitions for the mirror-image pattern. However, if participants struggle with the pattern, it is repeated until they learn it. Individuals execute the demonstrated pattern on the exercise mat and return to the beginning of the mat after completing it.
Study NCT05297370 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mixed and match Intervention
Description: Participants will receive a brief 15-minute counselling session based on the 5A's' and '5R's' models by our trained research assistant. Participants will be able to choose their smoking cessation treatment options from our menu.
Study NCT05297370 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants in the control group will receive a self-help quitting leaflet issued by the TACO
Study NCT05675904 — intervention group
Intervention type: PROCEDURE
Intervention: Colon oncological resection
Description: Scheduled colon cancer surgery
Study NCT06239493 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IVUS Guided
Description: Those already undergoing an IVUS guided percutaneous vascular intervention
Study NCT00722774 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H2N2 1960 AA ca recombinant vaccine
Description: Approximately 0.2 ml of 10\^7 TCID50 doses of vaccine administered intranasally
Study NCT05330156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral resection of the prostate
Description: - After an initial cysto-urethroscopy assessment done, Transurethral resection of the prostate is performed using the bipolar system with normal saline irrigation, under spinal or general anesthesia.
Study NCT05330156 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transurethral enucleation of prostate
Description: After an initial cysto-urethroscopy assessment done, transurethral enucleation of prostate is performed using the bipolar system with normal saline irrigation, under spinal or general anesthesia.
Study NCT05188040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Exercises
Description: Hand Therapy Exercises utilizing Oculus Quest 2 VR system with augmented feedback for patient to perform active hand therapy. Specific interventions / games will be selected by the participants individual therapist.
Study NCT04836962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 2cc of normal saline is administered to patient instead of dexamethasone.
Study NCT04836962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: dexamethasone is administered 0.5mg/kg (up to 10mg) which is diluted with normal saline to make a total of 2cc.
Study NCT05101746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitric Oxide (NO) 20 part per million (ppm)
Description: Nitric oxide will be mixed into the gas flow of the cardiopulmonary bypass (CPB) oxygenator, which will be kept at 1-3 L/min to allow for the desired NO delivery rate. NO levels will be maintained at 20ppm using a NO delivery system (INOmax, Mallinckrodt).
Study NCT05101746 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care cardiopulmonary bypass
Description: Cardiopulmonary bypass (CPB) will be performed using the departmental guidelines and standards. CPB will be performed using in a nonpulsatile flow with the System 1 Heart Lung Machine (Terumo Cardiovascular Systems, Ann Arbor, Mich). The maximum perfusion flow will be 200 ml/kg/minute. Blood pressure management will be selected based on the patient age and procedure. Temperature management will be to cool the patient 32 celsius (C).
Study NCT05139771 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: THE ENDOART® IMPLANTATION (Artificial Endothelial layer)
Description: Implantation of EndoArt® is similar to other anterior segment surgical procedures such as DSAEK/DMEK.
Study NCT05263050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Cabozantinib initiated at 40 mg daily. Dose-escalate or de-escalate based on pre-specified criteria and at set dosing schedules
Study NCT05263050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab injection is to be administered as an IV infusion at a dose of 480 mg on day 1 of each cycle
Study NCT05555459 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Operation
Description: Bone fixation operation in foot or ankle area using bioabsorbable headless screw/s
Study NCT04735549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Treatment
Description: Laser radiation is emitted by a series of pulses following each other through a pause. The duration of one pulse is 20-200 ns, the pause between pulses is 30 us. The energy of one pulse is about 1 mJ.~General laser radiation parameters for 1st and 2nd stages are: beam with diameter of 4 millimeters (mm) scans treatment area by 4 circles with step of 2 mm (50 percentage (%) overlap), average power of 10-25 Watt (W), treatment time in one point of 1-10 seconds (s), treatment step of 5 mm, from 1 to 5 repetitions of total vagina treatment. General laser radiation parameters for 3d stage are: beam diameter of 6 mm, average power of 15-30 W, duration of ns-pulses packet of 50-100 milliseconds (ms), pause between packets of 50-100 ms, treatment duration up to 65 s, treatment in permanent motion with speed of 10-50 mm/s.~The procedure is performed without anesthesia. The doctor always focuses on the participant's feeling of warmth.
Study NCT04735549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical hormone estriol
Description: Estriol ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Daily dose will be 0.5 gram daily for 2 weeks, later 0.5 gram twice a week for 12 months.
Study NCT04735549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical hormone estriol
Description: Estriol ((17 beta)-estra-1,3,5 (10)-trien-3,17-diol). Daily dose will be 0.5 gram daily for 2 weeks, later 0.5 gram twice a week for 12 months.
Study NCT04735549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Сlinical blood analysis
Description: Taking blood from a vein for Clinical blood analysis, Wassermann reaction (WR), human immunodeficiency viruses (HIV), hepatitis B infection (HBsAg), hepatitis C infection (HCVAg) determination, glucose test (to include the participant in the study).
Study NCT04735549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Сlinical blood analysis
Description: Taking blood from a vein for Clinical blood analysis, Wassermann reaction (WR), human immunodeficiency viruses (HIV), hepatitis B infection (HBsAg), hepatitis C infection (HCVAg) determination, glucose test (to include the participant in the study).
Study NCT04735549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Сlinical urine test
Description: Urine sampling for Clinical urine test (to include the participant in the study).
Study NCT04735549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Сlinical urine test
Description: Urine sampling for Clinical urine test (to include the participant in the study).
Study NCT04735549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vaginal smear
Description: Vaginal smear for flora investigation (to include the participant in the study), cytology, microbiological analysis with Gram staining (to evaluate procedure efficiency).
Study NCT04735549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal smear
Description: Vaginal smear for flora investigation (to include the participant in the study), cytology, microbiological analysis with Gram staining (to evaluate procedure efficiency).
Study NCT04735549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pelvic ultrasound
Description: Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
Study NCT04735549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic ultrasound
Description: Pelvic ultrasound investigation to determine pathologies of the pelvic through a gynecological probe (to include the participant in the study).
Study NCT04735549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Female Sexual Function Index
Description: Female Sexual Function Index will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
Study NCT04735549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Female Sexual Function Index
Description: Female Sexual Function Index will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
Study NCT04735549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire
Description: The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
Study NCT04735549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire
Description: The Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
Study NCT04735549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vulvovaginal Symptoms Questionnaire
Description: Vulvovaginal Symptoms Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
Study NCT04735549 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vulvovaginal Symptoms Questionnaire
Description: Vulvovaginal Symptoms Questionnaire will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).
Study NCT04735549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vaginal Health Index
Description: Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
Study NCT04735549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal Health Index
Description: Vaginal Health Index will be investigated by clinical examination for vaginal elasticity, vaginal secretions, epithelial mucous membrane, vaginal hydration. Potential of hydrogen (pH) will be investigated by test-lines paper (to evaluate procedure efficiency).
Study NCT04735549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Elastography (ultrasound investigation)
Description: Ultrasound investigation for assessing elasticity / stiffness of tissues of vulva region with Mindray device (head L14-6WU) (to evaluate procedure efficiency).
Study NCT04735549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Elastography (ultrasound investigation)
Description: Ultrasound investigation for assessing elasticity / stiffness of tissues of vulva region with Mindray device (head L14-6WU) (to evaluate procedure efficiency).
Study NCT04735549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Perineometry
Description: Pressure force of vaginal walls measurement with EmbaGYN device (to evaluate procedure efficiency).
Study NCT04735549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Perineometry
Description: Pressure force of vaginal walls measurement with EmbaGYN device (to evaluate procedure efficiency).
Study NCT04735549 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS)
Description: Visual Analogue Scale will be used to collect feedback on changes in the participants life quality (to evaluate procedure efficiency).